Compare ARDX & AMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | AMRC |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2014 | 2010 |
| Metric | ARDX | AMRC |
|---|---|---|
| Price | $6.33 | $25.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $15.14 | ★ $37.88 |
| AVG Volume (30 Days) | ★ 3.0M | 511.7K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.49 |
| Revenue | $2,607,000.00 | ★ $1,769,928,000.00 |
| Revenue This Year | $37.75 | $10.66 |
| Revenue Next Year | $34.24 | $9.07 |
| P/E Ratio | ★ N/A | $50.67 |
| Revenue Growth | N/A | ★ 28.76 |
| 52 Week Low | $3.50 | $8.49 |
| 52 Week High | $8.40 | $44.93 |
| Indicator | ARDX | AMRC |
|---|---|---|
| Relative Strength Index (RSI) | 59.74 | 47.79 |
| Support Level | $5.49 | $23.88 |
| Resistance Level | $6.70 | $31.12 |
| Average True Range (ATR) | 0.24 | 1.56 |
| MACD | 0.11 | 0.19 |
| Stochastic Oscillator | 87.88 | 47.47 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.